Cost-Effectiveness Analysis of Biopharmaceuticals for Treating Rheumatoid Arthritis: Infliximab, Adalimumab, and Etanercept

INTRODUCTION: Rheumatoid arthritis (RA) is a chronic progressive inflammatory disease that causes joint destruction. The condition imposes a significant economic burden on patients and societies. The present study is aimed at evaluating the cost-effectiveness of Infliximab, Adalimumab, and Etanercep...

Descripción completa

Detalles Bibliográficos
Autores principales: Gholami, Ahmad, Azizpoor, Jassem, Aflaki, Elham, Rezaee, Mehdi, Keshavarz, Khosro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8645365/
https://www.ncbi.nlm.nih.gov/pubmed/34877355
http://dx.doi.org/10.1155/2021/4450162

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8645365/
https://www.ncbi.nlm.nih.gov/pubmed/34877355
http://dx.doi.org/10.1155/2021/4450162

Ejemplares similares